Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy.
Piver
M Steven
MS
Department of Gynecologic Oncology Roswell Park Cancer Institute Buffalo, New York, USA.
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan